JPMorgan Chase & Co. Has $4.31 Million Holdings in CytomX Therapeutics, Inc. (CTMX)

JPMorgan Chase & Co. lowered its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 238,550 shares of the biotechnology company’s stock after selling 4,200 shares during the period. JPMorgan Chase & Co. owned approximately 0.62% of CytomX Therapeutics worth $4,310,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sphera Funds Management LTD. raised its stake in shares of CytomX Therapeutics by 5.0% during the third quarter. Sphera Funds Management LTD. now owns 210,000 shares of the biotechnology company’s stock valued at $3,816,000 after acquiring an additional 10,000 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $699,000. Macquarie Group Ltd. bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $107,000. Bank of New York Mellon Corp raised its stake in shares of CytomX Therapeutics by 11.6% during the third quarter. Bank of New York Mellon Corp now owns 129,182 shares of the biotechnology company’s stock valued at $2,347,000 after acquiring an additional 13,405 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of CytomX Therapeutics by 18.6% during the third quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock valued at $670,000 after acquiring an additional 5,800 shares in the last quarter. 63.13% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently weighed in on CTMX shares. BidaskClub downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Cowen reaffirmed an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Nomura lifted their price target on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 4th. Finally, Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a research note on Monday, October 23rd. They set an “overweight” rating and a $35.00 price target for the company. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $31.88.

CytomX Therapeutics, Inc. (NASDAQ CTMX) opened at $21.11 on Tuesday. The stock has a market cap of $847.68 and a P/E ratio of -13.45. CytomX Therapeutics, Inc. has a 1-year low of $10.40 and a 1-year high of $24.67.

In related news, CEO Sean A. Mccarthy sold 19,120 shares of CytomX Therapeutics stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.13, for a total transaction of $461,365.60. Following the transaction, the chief executive officer now directly owns 23,365 shares of the company’s stock, valued at $563,797.45. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frederick W. Gluck sold 10,000 shares of CytomX Therapeutics stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.27, for a total transaction of $242,700.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 140,947 shares of company stock worth $3,277,551. 8.00% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “JPMorgan Chase & Co. Has $4.31 Million Holdings in CytomX Therapeutics, Inc. (CTMX)” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/01/02/jpmorgan-chase-co-has-4-31-million-holdings-in-cytomx-therapeutics-inc-ctmx.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply